column
Research and development of Chinese anti-COVID-19 drugs
Xiwei Ji, Xiangrui Meng, Xiao Zhu, Qingfeng He, Yimin Cui,
2022, 12(12):4271-4286. DOI:10.1016/j.apsb.2022.09.002
Abstract
Small molecule-based immunomodulators for cancer therapy
Yinrong Wu, Zichao Yang, Kui Cheng, Huichang Bi, Jianjun Chen,
2022, 12(12):4287-4308. DOI:10.1016/j.apsb.2022.11.007
Abstract
Harnessing the cyclization strategy for new drug discovery
Kai Tang, Shu Wang, Wenshuo Gao, Yihui Song, Bin Yu,
2022, 12(12):4309-4326. DOI:10.1016/j.apsb.2022.09.022
Abstract
Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
Yanyan Xua, Jingyuan Xiongb, Xiyang Sunc, Huile Gao,
2022, 12(12):4327-4347. DOI:10.1016/j.apsb.2022.11.001
Abstract
Recent advances in bacteriophage-based therapeutics: Insight into the post-antibiotic era
Hao Ling, Xinyu Lou, Qiuhua Luo, Zhonggui He, Mengchi Sun, Jin Sun,
2022, 12(12):4348-4364. DOI:10.1016/j.apsb.2022.05.007
Abstract
Evolution of drug regulations and regulatory innovation for anticancer drugs in China
Yang Liu, Ning Zhang, Cuicui Xie, Yale Jiang, Yunhe Qin, Liyun Zhou, Yi Fan, Lianjie Ren, Chen Yin, Huan Yang, Wei Xie, Qing Zhai, Guanqiao Li, Hongzhuan Chenf, Xiaoyuan Chen,
2022, 12(12):4365-4377. DOI:10.1016/j.apsb.2022.08.004
Abstract
Repurposing of berbamine hydrochloride to inhibit Ebola virus by targeting viral glycoprotein
Dongrong Yi, Quanjie Li Han Wang, Kai Lv, Ling Ma, Yujia Wang, Jing Wang, Yongxin Zhang, Mingliang Liu, Xiaoyu Li, Jianxun Qi, Yi Shi, George F. Gao, Shan Cen, ,
2022, 12(12):4378-4389. DOI:10.1016/j.apsb.2022.05.023
Abstract
Sphingosine kinase 1 promotes growth of glioblastoma by increasing inflammation mediated by the NF-kB /IL-6/STAT3 and JNK/PTX3 pathways
Wan Li, Hongqing Cai, Liwen Ren, Yihui Yang, Hong Yang, Jinyi Liu, Sha Li, Yizhi Zhang, Xiangjin Zheng, Wei Tan, Guanhua Du, Jinhua Wang,
2022, 12(12):4390-4406. DOI:10.1016/j.apsb.2022.09.012
Abstract
Highly expressed SERCA2 triggers tumor cell autophagy and is a druggable vulnerability in triple-negative breast cancer
Minmin Fan, Jian Gao, Lin Zhou, Wenwen Xue, Yixuan Wang, Jingwei Chen, Wuhao Li, Ying Yu, Bo Liu, Yan Shen, Qiang Xu, ,
2022, 12(12):4407-4423. DOI:10.1016/j.apsb.2022.05.009
Abstract
Landscape of DILI-related adverse drug reaction in China Mainland
Jiabo Wang, Haibo Song, Feilin Ge, Peng Xiong, Jing Jing, Tingting He, Yuming Guo, Zhuo Shi, Chao Zhou, Zixin Han, Yanzhong Han, Ming Niu, Zhaofang Bai, Guangbin Luo, Chuanyong Shen, Xiaohe Xiao,
2022, 12(12):4424-4431. DOI:10.1016/j.apsb.2022.04.019
Abstract
Fully synthetic Tn-based three-component cancer vaccine using covalently linked TLR4 ligand MPLA and iNKT cell agonist KRN-7000 as built-in adjuvant effectively protects mice from tumor development
Deying Yang, Xiang Luo, Qinghai Lian, Lingqiang Gao, Chengxin Wang, Xiaoxiao Qi, Rong Zhang, Zhongqiu Liu, Guochao Liao,
2022, 12(12):4432-4445. DOI:10.1016/j.apsb.2022.05.028
Abstract
Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
Chengliang Sun, Yao Cheng, Xiaojia Liu, Gefei Wang, Wenjian Min, Xiao Wang, Kai Yuan, Yi Hou, Jiaxing Li, Haolin Zhang, Haojie Dong, Liping Wang, Chenguang Lou, Yanze Sun, Xinmiao Yu, Hongbin Deng, Yibei Xiao, Peng Yang,
2022, 12(12):4446-4457. DOI:10.1016/j.apsb.2022.04.007
Abstract
Co-delivery of nigericin and decitabine using hexahistidine-metal nanocarriers for pyroptosis-induced immunotherapeutics
Qiang Niu, Yu Liu, Yujing Zheng, Ziwei Tang, Yuna Qian, Ruogu Qi, Jianliang Shen, Ping Zhao,
2022, 12(12):4458-4471. DOI:10.1016/j.apsb.2022.11.002
Abstract
Biodegradable calcium sulfide-based nanomodulators for H2S-boosted Ca2+-involved synergistic cascade cancer therapy
Chuchu Lin, Chenyi Huang, Zhaoqing Shi, Meitong Ou, Shengjie Sun, Mian Yu, Ting Chen, Yunfei Yi, Xiaoyuan Ji, Feng Lv, Meiying Wu, Lin Mei,
2022, 12(12):4472-4485. DOI:10.1016/j.apsb.2022.08.008
Abstract
Spatio-temporal delivery of both intra-and extracellular toll-like receptor agonists for enhancing antigen-specific immune responses
Nannan Wang, Yueyue Zuo, Shengjie Wu, Chenlu Huang, Linhua Zhang, Dunwan Zhu,
2022, 12(12):4486-4500. DOI:10.1016/j.apsb.2022.05.032
Abstract
Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
Yuling Mao, Xiudan Wang, Caishun Chen, Qinfu Zhao, Yanfeng Liu, Jinghai Zhang, Siling Wang,
2022, 12(12):4501-4518. DOI:10.1016/j.apsb.2022.04.018
Abstract
SMIP-30, a potent and selective PPM1A inhibitor with potential to treat tuberculosis
Shujing Xu, Xinyong Liu, Peng Zhan,
2022, 12(12):4519-4521. DOI:10.1016/j.apsb.2022.10.001
Abstract
Commentary: Acute psychological stress redistributed leukocytes via distinct brain circuits
Yan-Ping Wu, Rong-Rong He,
2022, 12(12):4522-4524. DOI:10.1016/j.apsb.2022.10.009
Abstract
Author correction to ‘Multifunctional regulatory protein connective tissue growth factor (CTGF): A potential therapeutic target for diverse diseases’ [Acta pharmaceutica sinica B 12 (2022) 1740-1760]
Minyang Fu, Dandan Peng, Tianxia Lan, Yuquan Wei, Xiawei Wei,
2022, 12(12):4525-4525. DOI:10.1016/j.apsb.2022.01.007
Abstract

Copyright © 2014 Editorial Office of Acta Pharmaceutica Sinica